---
schema_version: "secwatch.filing_event.v1"
accession: "0001773751-24-000337"
form_type: "8-K"
ticker: "HIMS"
cik: "0001773751"
company_name: "Hims & Hers Health, Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:13:12.717474+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Hims & Hers Q3 rev $401.6M (+77% YoY), net income $75.6M, raises FY guidance

## Summary
- Q3 2024: Revenue $401.6M (+77% YoY), net income $75.6M (vs -$7.6M), Adj EBITDA $51.1M.
- Subscribers 2.0M (+44% YoY); over 1M using personalized solutions; ex-GLP-1 sub growth 40% YoY.
- FY 2024 guidance raised: Revenue $1.460-1.465B, Adj EBITDA $173-178M.
- Weight loss offering: oral GLP-1 $100M annual run rate; 80K reports of supply shortage; planning liraglutide in 2025.

## SEC filing metadata
- accession: 0001773751-24-000337
- form_type: 8-K
- ticker: HIMS
- cik: 0001773751
- company_name: Hims & Hers Health, Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1773751/000177375124000337/0001773751-24-000337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1773751/000177375124000337/hims-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001773751-24-000337
- JSON: https://secwatch.observer/filing/0001773751-24-000337.json
- Plain text: https://secwatch.observer/filing/0001773751-24-000337.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.